Advertisement

Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial

  • Arash Ghasemi
  • Zahra Ghashghai
  • Jafar Akbari
  • Jamshid Yazdani-Charati
  • Ebrahim Salehifar
  • Seyed Jalal Hosseinimehr
Clinical Trial

Abstract

Background and purpose

The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of topical administration of atorvastatin (ATV) on the acute radiation-induced skin toxicity in patients with breast cancer.

Patients and methods

Seventy breast cancer patients were randomly assigned to use topical ATV 1% or placebo gels during radiotherapy twice daily. Radiation-induced dermatitis was classified according to the radiation therapy oncology group (RTOG) criteria, as well as pain and itching were scored according to VAS (visual analogue scale) for 6 weeks of treatment.

Results

Topical administration of ATV gel during radiotherapy reduced significantly radiation-induced breast swelling, itching, and pain in breast cancer patients by factors of 1.8, 1.7, and 1.5, respectively. ATV reduced the redness caused by radiotherapy in patients as compared with placebo; however, this difference was statistically not significant.

Conclusion

ATV was able to reduce significantly itching, breast edema, and pain in patients during radiotherapy.

Keywords

Atorvastatin Skin toxicity Radiotherapy Radioprotective 

Notes

Acknowledgments

This research was the subject of a thesis of Zahra Ghashghaei as a Pharm D. student of Mazandaran University of Medical Science.

Funding information

This study was supported by a grant from Mazandaran University of Medical Science, Sari, Iran.

Compliance with ethical standards

Conflict of interest statement

The authors declare that they had no conflicts of interest.

Supplementary material

228_2018_2570_MOESM1_ESM.docx (16 kb)
ESM 1 (DOCX 16.3 kb)

References

  1. 1.
    Ghoncheh M, Pournamdar Z, Salehiniya H (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17(S3):43–46CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917.  https://doi.org/10.1002/ijc.25516 CrossRefPubMedGoogle Scholar
  3. 3.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast Cancer cooperative group 82b trial. N Engl J Med 337(14):949–955.  https://doi.org/10.1056/NEJM199710023371401 CrossRefPubMedGoogle Scholar
  4. 4.
    Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P, Group OCO (2000) The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Cancer 88(10):2260–2266CrossRefGoogle Scholar
  5. 5.
    Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P (2000) The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical Oncology Group. Cancer 88(10):2260–2266CrossRefGoogle Scholar
  6. 6.
    Chan RJ, Keller J, Cheuk R, Blades R, Tripcony L, Keogh S (2012) A double-blind randomised controlled trial of a natural oil-based emulsion (Moogoo Udder Cream®) containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer. Radiat Oncol 7:121.  https://doi.org/10.1186/1748-717X-7-121 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Heggie S, Bryant GP, Tripcony L, Keller J, Rose P, Glendenning M, Heath J (2002) A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs 25(6):442–451CrossRefGoogle Scholar
  8. 8.
    Kang HC, Ahn SD, Choi DH, Kang MK, Chung WK, Wu HG (2014) The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study. Radiat Oncol J 32(3):156–162.  https://doi.org/10.3857/roj.2014.32.3.156 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Shukla PN, Gairola M, Mohanti BK, Rath GK (2006) Prophylactic beclomethasone spray to the skin during postoperative radiotherapy of carcinoma breast: a prospective randomized study. Indian J Cancer 43(4):180–184CrossRefGoogle Scholar
  10. 10.
    Fenig E, Brenner B, Katz A, Sulkes J, Lapidot M, Schachter J, Malik H, Sulkes A, Gutman H (2001) Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial. Oncol Rep 8(2):305–309PubMedGoogle Scholar
  11. 11.
    Hosseinimehr SJ (2014) The use of angiotensin II receptor antagonists to increase the efficacy of radiotherapy in cancer treatment. Future Oncol 10(15):2381–2390.  https://doi.org/10.2217/fon.14.177 CrossRefPubMedGoogle Scholar
  12. 12.
    Salehifar E, Hosseinimehr SJ (2016) The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers. Drug Discov Today 21(4):654–662.  https://doi.org/10.1016/j.drudis.2016.02.019 CrossRefPubMedGoogle Scholar
  13. 13.
    Farsaei S, Khalili H, Farboud ES (2012) Potential role of statins on wound healing: review of the literature. Int Wound J 9(3):238–247.  https://doi.org/10.1111/j.1742-481X.2011.00888.x CrossRefPubMedGoogle Scholar
  14. 14.
    Jowkar F, Namazi MR (2010) Statins in dermatology. Int J Dermatol 49(11):1235–1243.  https://doi.org/10.1111/j.1365-4632.2010.04579.x CrossRefPubMedGoogle Scholar
  15. 15.
    Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6(12):1833–1846.  https://doi.org/10.1016/j.intimp.2006.08.006 CrossRefPubMedGoogle Scholar
  16. 16.
    Khattri S, Zandman-Goddard G (2013) Statins and autoimmunity. Immunol Res 56(2–3):348–357.  https://doi.org/10.1007/s12026-013-8409-8 CrossRefPubMedGoogle Scholar
  17. 17.
    Asai J, Takenaka H, Hirakawa S, Sakabe J, Hagura A, Kishimoto S, Maruyama K, Kajiya K, Kinoshita S, Tokura Y, Katoh N (2012) Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am J Pathol 181(6):2217–2224.  https://doi.org/10.1016/j.ajpath.2012.08.023 CrossRefPubMedGoogle Scholar
  18. 18.
    Bracht L, Caparroz-Assef SM, Magon TF, Ritter AM, Cuman RK, Bersani-Amado CA (2011) Topical anti-inflammatory effect of hypocholesterolaemic drugs. J Pharm Pharmacol 63(7):971–975.  https://doi.org/10.1111/j.2042-7158.2011.01302.x CrossRefPubMedGoogle Scholar
  19. 19.
    Suzuki-Banhesse VF, Azevedo FF, Araujo EP, do Amaral ME, Caricilli AM, Saad MJ, Lima MH (2015) Effect of atorvastatin on wound healing in rats. Biol Res Nurs 17(2):159–168.  https://doi.org/10.1177/1099800414537348 CrossRefPubMedGoogle Scholar
  20. 20.
    Soehnlein O, Eskafi S, Schmeisser A, Kloos H, Daniel WG, Garlichs CD (2004) Atorvastatin induces tissue transglutaminase in human endothelial cells. Biochem Biophys Res Commun 322(1):105–109.  https://doi.org/10.1016/j.bbrc.2004.07.087 CrossRefPubMedGoogle Scholar
  21. 21.
    Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152(2):359–366CrossRefGoogle Scholar
  22. 22.
    Chang CZ, Wu SC, Lin CL, Hwang SL, Howng SL, Kwan AL (2010) Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats. Acta Neurochir 152(8):1399–1406; discussion 1405-1396.  https://doi.org/10.1007/s00701-010-0652-3 CrossRefPubMedGoogle Scholar
  23. 23.
    Pathak NN, Balaganur V, Lingaraju MC, More AS, Kant V, Kumar D, Kumar D, Tandan SK (2013) Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats. Inflammation 36(6):1468–1478.  https://doi.org/10.1007/s10753-013-9688-x CrossRefPubMedGoogle Scholar
  24. 24.
    Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP (2010) Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 18(4):169–177.  https://doi.org/10.1007/s10787-010-0044-6 CrossRefPubMedGoogle Scholar
  25. 25.
    Farsaei S, Khalili H, Farboud ES, Karimzadeh I, Beigmohammadi MT (2014) Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial. Pharmacotherapy 34(1):19–27.  https://doi.org/10.1002/phar.1339 CrossRefPubMedGoogle Scholar
  26. 26.
    Toker S, Gulcan E, Cayc MK, Olgun EG, Erbilen E, Ozay Y (2009) Topical atorvastatin in the treatment of diabetic wounds. Am J Med Sci 338(3):201–204.  https://doi.org/10.1097/MAJ.0b013e3181aaf209 CrossRefPubMedGoogle Scholar
  27. 27.
    Jacobson G, Bhatia S, Smith BJ, Button AM, Bodeker K, Buatti J (2013) Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys 85(3):604–608.  https://doi.org/10.1016/j.ijrobp.2012.06.042 CrossRefPubMedGoogle Scholar
  28. 28.
    Rao S, Hegde SK, Baliga-Rao MP, Lobo J, Palatty PL, George T, Baliga MS (2017) Sandalwood oil and turmeric-based cream prevents ionizing radiation-induced dermatitis in breast cancer patients: clinical study. Medicines (Basel) 4(3)  https://doi.org/10.3390/medicines4030043 CrossRefGoogle Scholar
  29. 29.
    Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346CrossRefGoogle Scholar
  30. 30.
    Pezner RD, Patterson MP, Hill LR, Desai KR, Vora N, Lipsett JA (1985) Breast edema in patients treated conservatively for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 11(10):1765–1768CrossRefGoogle Scholar
  31. 31.
    Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, Lala M, Martinez A, Schell S, Vicini FA (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1375–1380.  https://doi.org/10.1016/j.ijrobp.2007.02.044 CrossRefPubMedGoogle Scholar
  32. 32.
    Berthelet E, Truong PT, Musso K, Grant V, Kwan W, Moravan V, Patterson K, Olivotto IA (2004) Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol 27(6):626–631CrossRefGoogle Scholar
  33. 33.
    Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR (2009) Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys 74(3):689–694.  https://doi.org/10.1016/j.ijrobp.2008.08.071 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zygogianni A, Kouloulias V, Antypas C, Armpilia C, Kyrgias G, Kouvaris J (2014) The impact of intermediate time between chemotherapy and hypofractionated radiotherapy to the radiation induced skin toxicity for breast adjuvant treatment. Breast J 20(1):74–78.  https://doi.org/10.1111/tbj.12206 CrossRefPubMedGoogle Scholar
  35. 35.
    James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE (2008) Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev (3): CD003860.  https://doi.org/10.1002/14651858.CD003860.pub2
  36. 36.
    Harper JL, Franklin LE, Jenrette JM, Aguero EG (2004) Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97(10):989–993.  https://doi.org/10.1097/01.SMJ.0000140866.97278.87 CrossRefPubMedGoogle Scholar
  37. 37.
    Hosseinimehr SJ, Izakmehri M, Ghasemi A (2015) In vitro protective effect of atorvastatin against ionizing radiation induced genotoxicity in human lymphocytes. Cell Mol Biol (Noisy-le-grand) 61(1):68–71Google Scholar
  38. 38.
    Hamzeh M, Talebpour Amiri F, Karimpour Malekshah A, Yaghubi Beklar S, Hosseinimehr J (2017) Protective effect of atorvastatin against cardiotoxicity and hematotoxicity induced by cyclophosphamide in rat. J Mazand Univ Med Sci 27(151):1–11Google Scholar
  39. 39.
    Talebpour Amiri F, Hamzeh M, Naeimi RA, Ghasemi A, Hosseinimehr SJ (2018) Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice. Int J Radiat Biol 94(2):106–113.  https://doi.org/10.1080/09553002.2018.1420926 CrossRefPubMedGoogle Scholar
  40. 40.
    Naeimi RA, Talebpour Amiri F, Khalatbary AR, Ghasemi A, Zargari M, Ghesemi M, Hosseinimehr SJ (2017) Atorvastatin mitigates testicular injuries induced by ionizing radiation in mice. Reprod Toxicol 72:115–121.  https://doi.org/10.1016/j.reprotox.2017.06.052 CrossRefPubMedGoogle Scholar
  41. 41.
    Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE (2011) The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol (R Coll Radiol) 23(10):662–673.  https://doi.org/10.1016/j.clon.2011.04.011 CrossRefGoogle Scholar
  42. 42.
    Verbelen H, Gebruers N, Beyers T, De Monie AC, Tjalma W (2014) Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: a systematic review. Breast Cancer Res Treat 147(3):463–471.  https://doi.org/10.1007/s10549-014-3110-8 CrossRefPubMedGoogle Scholar
  43. 43.
    Adriaenssens N, Verbelen H, Lievens P, Lamote J (2012) Lymphedema of the operated and irradiated breast in breast cancer patients following breast conserving surgery and radiotherapy. Lymphology 45(4):154–164PubMedGoogle Scholar
  44. 44.
    Bani HA, Fasching PA, Lux MM, Rauh C, Willner M, Eder I, Loehberg C, Schrauder M, Beckmann MW, Bani MR (2007) Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. Patient Educ Couns 66(3):311–318.  https://doi.org/10.1016/j.pec.2007.01.004 CrossRefPubMedGoogle Scholar
  45. 45.
    Huang Z, Rose AH, Hoffmann PR (2012) The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16(7):705–743.  https://doi.org/10.1089/ars.2011.4145 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Pfister C, Dawzcynski H, Schingale FJ (2016) Sodium selenite and cancer related lymphedema: biological and pharmacological effects. J Trace Elem Med Biol 37:111–116.  https://doi.org/10.1016/j.jtemb.2016.05.005 CrossRefPubMedGoogle Scholar
  47. 47.
    Kulkarni NM, Muley MM, Jaji MS, Vijaykanth G, Raghul J, Reddy NK, Vishwakarma SL, Rajesh NB, Mookkan J, Krishnan UM, Narayanan S (2015) Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-kappaB activation. Arch Pharm Res 38(6):1238–1247.  https://doi.org/10.1007/s12272-014-0496-0 CrossRefPubMedGoogle Scholar
  48. 48.
    McGown CC, Brookes ZL, Hellewell PG, Ross JJ, Brown NJ (2015) Atorvastatin reduces endotoxin-induced microvascular inflammation via NOSII. Naunyn Schmiedeberg's Arch Pharmacol 388(5):557–564.  https://doi.org/10.1007/s00210-015-1100-y CrossRefGoogle Scholar
  49. 49.
    Kindgen-Milles D (1995) Effects of prostaglandin E2 on the intensity of bradykinin-evoked pain from skin and veins of humans. Eur J Pharmacol 294(2–3):491–496CrossRefGoogle Scholar
  50. 50.
    Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga JT, Parada CA, Verri WA Jr, Cunha FQ, Ferreira SH (2008) 15d-prostaglandin J2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor. J Pharmacol Exp Ther 324(1):313–321.  https://doi.org/10.1124/jpet.107.126045 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiology and Radiation Oncology, Faculty of MedicineMazandaran University of Medical SciencesSariIran
  2. 2.Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research CenterMazandaran University of Medical SciencesSariIran
  3. 3.Student Research CommitteeMazandaran University of Medical SciencesSariIran
  4. 4.Department of Pharmaceutics, Faculty of PharmacyMazandaran University of Medical SciencesSariIran
  5. 5.Department of Biostatistics, Health Sciences Research Center, Addiction InstituteMazandaran University of Medical SciencesSariIran
  6. 6.Department of Clinical Pharmacy, Faculty of PharmacyMazandaran University of Medical SciencesSariIran

Personalised recommendations